In recent years, protein tyrosine phosphatase SHP2 has become a highly regarded research target in the field of oncology in mediating the RAS-driven MAPK signaling pathway. Its treatment methods are not limited to single drug use, but also can work together with KRAS inhibitors, showing good ...
In the process of developing new drugs, chiral dihydroazaindolecarboxylic acid (R)-1 is in great demand as a key starting material for the synthesis of active pharmaceutical ingredients (APIs). However, the traditional synthesis method, chiral supercritical fluid chromatographic separation, is ...
MRTX0902 is a highly effective SOS1:KRAS complex inhibitor that exhibits excellent brain penetration, high oral bioavailability, and strong selectivity. When combined with MRTX849 (1,2)-adagrasib (KRAZATI), it can significantly enhance its anti-tumor activity.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
